Document Detail


Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.
MedLine Citation:
PMID:  22437966     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sub-Saharan African children have an increased incidence of Wilms' tumor (WT) and experience alarmingly poor outcomes. Although these outcomes are largely due to inadequate therapy, we hypothesized that WT from this region exhibits features of biological aggressiveness that may warrant broader implementation of high-risk therapeutic protocols. We evaluated 15 Kenyan WT (KWT) for features of aggressive disease (blastemal predominance and Ki67/cellular proliferation) and treatment resistance (anaplasia and p53 immunopositivity). To explore the additional biological features of KWT, we determined the mutational status of the CTNNB1/β-catenin and WT1 genes and performed immunostaining for markers of Wnt pathway activation (β-catenin) and nephronic progenitor cell self-renewal (WT1, CITED1 and SIX2). We characterized the proteome of KWT using imaging mass spectrometry (IMS). The results were compared to histology- and age-matched North American WT (NAWT) controls. For patients with KWT, blastemal predominance was noted in 53.3% and anaplasia in 13%. We detected increased loss to follow-up (p = 0.028), disease relapse (p = 0.044), mortality (p = 0.001) and nuclear unrest (p = 0.001) in patients with KWT compared to controls. KWT and NAWT showed similar Ki67/cellular proliferation. We detected an increased proportion of epithelial nuclear β-catenin in KWT (p = 0.013). All 15 KWT specimens were found to harbor wild-type CTNNB1/β-catenin, and one contained a WT1 nonsense mutation. WT1 was detected by immunostaining in 100% of KWT, CITED1 in 80% and SIX2 in 80%. IMS revealed a molecular signature unique to KWT that was distinct from NAWT. The African WT specimens appear to express markers of adverse clinical behavior and treatment resistance and may require alternative therapies or implementation of high-risk treatment protocols.
Authors:
Andrew J Murphy; Jason R Axt; Christian de Caestecker; Janene Pierce; Hernan Correa; Erin H Seeley; Richard M Caprioli; Mark W Newton; Mark P de Caestecker; Harold N Lovvorn
Related Documents :
1696006 - Cell differentiation in sacrococcygeal teratomas. an immunohistochemical and follow-up ...
6091306 - Placental site trophoblastic tumor of the uterus: an ultrastructural and immunohistoche...
2835146 - Extraskeletal myxoid chondrosarcoma in young children.
1357816 - Establishment and characterization of a cell line of congenital primitive neuroectoderm...
15131056 - Development of a new isogenic cell-xenograft system for evaluation of nad(p)h:quinone o...
12125976 - The alteration of prostaglandin e2 levels in patients with brain tumors before and afte...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2012-04-04
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  131     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-07-23     Completed Date:  2013-03-11     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E983-94     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 UICC.
Affiliation:
Department of Pediatric Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. andrew.j.murphy@vanderbilt.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Africa South of the Sahara
Child, Preschool
Female
Genes, Wilms Tumor
Humans
Infant
Kidney Neoplasms / genetics*,  mortality,  pathology
Male
Mass Spectrometry
Mutation
Nuclear Proteins / analysis
Prognosis
Transcription Factors / analysis
Tumor Suppressor Protein p53 / analysis
Wilms Tumor / genetics*,  mortality,  pathology
beta Catenin / analysis,  genetics
Grant Support
ID/Acronym/Agency:
4R00CA135695-03/CA/NCI NIH HHS; 5T32CA106183-06A1/CA/NCI NIH HHS; KL2 RR024977/RR/NCRR NIH HHS; KL2 TR000446/TR/NCATS NIH HHS; P30-CA68485/CA/NCI NIH HHS; T32 CA106183-06A1/CA/NCI NIH HHS; TL1 RR024978/RR/NCRR NIH HHS; TL1 TR000447/TR/NCATS NIH HHS; UL1 RR024975/RR/NCRR NIH HHS; UL1 RR024975/RR/NCRR NIH HHS; UL1 TR000445/TR/NCATS NIH HHS
Chemical
Reg. No./Substance:
0/CITED1 protein, human; 0/CTNNB1 protein, human; 0/Nuclear Proteins; 0/Transcription Factors; 0/Tumor Suppressor Protein p53; 0/beta Catenin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Core-modified hexaphyrin: synthesis and characterization of 31,34-disilahexaphyrinoid.
Next Document:  Low fluence-high repetition rate diode laser hair removal 12-month evaluation: Reducing pain and ris...